Automate Your Wheel Strategy on LTRN
With Tiblio's Option Bot, you can configure your own wheel strategy including LTRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LTRN
- Rev/Share 0.0093
- Book/Share 1.1611
- PB 3.6086
- Debt/Equity 0.0116
- CurrentRatio 3.5216
- ROIC -1.6018
- MktCap 45249486.0
- FreeCF/Share -1.6574
- PFCF -2.5316
- PE -2.3476
- Debt/Assets 0.0083
- DivYield 0
- ROE -0.9988
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent, expected to be granted in the coming months with exclusivity through early 2039, strengthens Lantern's global intellectual property.
Read More
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operator Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
Read More
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve.
Read More
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Read More
About Lantern Pharma Inc. (LTRN)
- IPO Date 2020-06-11
- Website https://www.lanternpharma.com
- Industry Biotechnology
- CEO Panna Sharma
- Employees 24